

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/556,145-Conf. #5957
				Filing Date	August 21, 2006
				First Named Inventor	Richard BELIVEAU
				Art Unit	1643
				Examiner Name	A. Gussow
Sheet	1	of	1	Attorney Docket Number	0480-0165PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Richardson, et al., "The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell," Eur.J.Biochem., Vol 267, pp 1290-1298 (2000).	
	CB	Sekyere, et al., "Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human," Biochimica, Vol 1722, pp 131-142 (2005)	
	CC	Dunn, et al., "The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis," Carcinogenesis, Vol 27, No 11, pp 2157-2169 (2006).	
	CD	Rahmanto, et al., "Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo," Carcinogenesis, Vol 28, No 10, pp 2172-2183 (2007)	
	CE	Sekyere, et al., "Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo," Blood, Vol 107, pp 2599-2601 (2006)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.